At 10.6% CAGR, the Middle East & Africa Molecular Diagnostics for Infectious Disease Market is Projected to be Worth US$ 301.21 Million by 2030, Says Business Market Insights

According to Business Market Insights research, the Middle East & Africa molecular diagnostics for infectious disease market was valued at US$ 134.22 million in 2022 and is expected to reach US$ 301.21 million by 2030, registering a CAGR of 10.6% from 2022 to 2030. Rising application of molecular diagnostics in veterinary infectious diseases and surging prevalence of infectious disease globally are among the critical factors attributed to the Middle East & Africa molecular diagnostics for infectious disease market expansion.

Public health is adversely affected by infectious diseases, causing morbidity, mortality, and economic burdens. Infectious diseases are on the rise, necessitating accurate and timely diagnosis to form the basis for effective disease management, treatment, and prevention. Diagnosing and monitoring multiple infections and diseases-including HIV, tuberculosis, hepatitis C, human papillomavirus screening for cervical cancer, and sexually transmitted infections, as well as outbreaks of infections-can be performed using molecular diagnostics techniques, laboratory-based assays, and point-of-care tests. According to an article published in the National Library of Medicine (NLM) in 2021, infectious diseases are a major problem in most African countries due to limited healthcare resources and the high disease burden. More than 200 pathogens can cause fever in Nigeria, one of the most common reasons for visiting a healthcare facility. These pathogens include malaria parasites, Salmonella enterica and hemorrhagic viruses. It is impossible to reliably detect life-threatening pathogens with only culture results. Therefore, efficient molecular diagnostics are essential in areas with high infectious disease burdens.

A resurgence in certain infectious diseases has been observed over the past few years. For instance, the reemergence of diseases such as tuberculosis, malaria, and hepatitis has necessitated the development of effective diagnostic tools to identify the causative agents and determine effective treatment regimens. According to the World Health Organization (WHO), ~10.6 million cases of tuberculosis were reported globally in 2021, which is equivalent to 134 cases per 100,000 people. TB cases are reported as follows in countries such as. In 2021, four countries recorded malaria deaths as follows: Nigeria (31%), the Democratic Republic of the Congo (13%), Niger (4%), and Tanzania (4%). According to the WHO African Region's estimates, there were roughly 40 million pregnancies in 38 moderate and high transmission countries in 2021, of which 13.3 million (32%) contracted malaria during pregnancy. Thus, the surging prevalence of infectious disease propels the need for molecular diagnostic technology over traditional techniques, such as microbial culture, hemagglutination inhibition tests, and enzyme-linked immunosorbent assays (ELISA).

On the contrary, limitations associated with molecular testing hampers the growth Middle East & Africa molecular diagnostics for infectious disease market.

Based on type, the Middle East & Africa molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The laboratory testing segment held 59.0% share of Middle East & Africa molecular diagnostics for infectious disease market in 2022, amassing US$ 79.24 million. It is projected to garner US$ 174.19 million by 2030 to expand at 10.3% CAGR during 2022-2030.

The Middle East & Africa molecular diagnostics for infectious disease market, by end user, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further bifurcated into human testing and vet testing. Similarly, laboratory testing is further bifurcated into human testing and vet testing. The human testing segment, by point-of-care testing, held 95.7% share of the Middle East & Africa molecular diagnostics for infectious disease market in 2022, amassing US$ 52.61 million. It is projected to garner US$ 120.66 million by 2030 to expand at 10.9% CAGR during 2022-2030. Additionally, the human testing segment, by laboratory testing, held 95.1% share of the Middle East & Africa molecular diagnostics for infectious disease market in 2022, amassing US$ 75.36 million. It is projected to garner US$ 164.48 million by 2030 to expand at 10.2% CAGR during 2022-2030.

Based on application, the Middle East & Africa molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into detection of single pathogen, detection of two or more pathogens, evaluation of emerging novel infections, surveillance and early detection of biothreat agents and diseases-related biomarker, and antimicrobial resistance profiling. Similarly, laboratory testing is further categorized into patient stratification, drug regimen selection, toxicity avoidance, therapeutic monitoring, and detection of predisposition to disease. The detection of a single pathogen segment, by point-of-care testing, held 45.3% share of the Middle East & Africa molecular diagnostics for infectious disease market in 2022, amassing US$ 24.88 million. It is projected to garner US$ 56.24 million by 2030 to expand at 10.7% CAGR during 2022-2030. Additionally, the drug regimen selection segment, by laboratory testing, held 36.6% share of the Middle East & Africa molecular diagnostics for infectious disease market in 2022, amassing US$ 28.97 million. It is projected to garner US$ 63.41 million by 2030 to expand at 10.3% CAGR during 2022-2030.

Based on disease type, the Middle East & Africa molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into sepsis (e.g. urogenital/lung/wound), prosthetic joint infection, endocarditis, STDs, mononucleosis, group A streptococcus, and others. Similarly, laboratory testing is further categorized into sepsis, prosthetic joint infection, endocarditis, STDs, chlamydia, gastrointestinal infection, tuberculosis, H1N1 virus, and others. The STDs segment, by point-of-care testing, held 65.3% share of the Middle East & Africa molecular diagnostics for infectious disease market in 2022, amassing US$ 35.91 million. It is projected to garner US$ 84.49 million by 2030 to expand at 11.3% CAGR during 2022-2030. Additionally, the STDs segment, by laboratory testing, held 54.0% share of the Middle East & Africa molecular diagnostics for infectious disease market in 2022, amassing US$ 42.76 million. It is projected to garner US$ 96.24 million by 2030 to expand at 10.7% CAGR during 2022-2030.

Based on infection type, the Middle East & Africa molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The Point-of-care testing is further segmented into bacteria, viral, fungi, and others. Similarly, laboratory testing is further categorized into bacteria, viral, fungi, and others. The bacteria segment, by point-of-care testing, held 47.8% share of the Middle East & Africa molecular diagnostics for infectious disease market in 2022, amassing US$ 26.28 million. It is projected to garner US$ 59.58 million by 2030 to expand at 10.8% CAGR during 2022-2030. Additionally, the bacteria segment, by laboratory testing, held 47.6% share of the Middle East & Africa molecular diagnostics for infectious disease market in 2022, amassing US$ 37.70 million. It is projected to garner US$ 81.35 million by 2030 to expand at 10.1% CAGR during 2022-2030.

Based on country, the Middle East & Africa molecular diagnostics for infectious disease market is categorized into Saudi Arabia, the UAE, South Africa, and the Rest of Middle East & Africa. Saudi Arabia held 46.3% share of Middle East & Africa molecular diagnostics for infectious disease market in 2022, amassing US$ 62.16 million. It is projected to garner US$ 137.54 million by 2030 to expand at 10.4% CAGR during 2022-2030.

Key players operating in the Middle East & Africa molecular diagnostics for infectious disease market are F. Hoffmann-La Roche Ltd, Abbott Laboratories, Thermo Fisher Scientific Inc, bioMerieux SA, Danaher Corp, Hologic Inc, Siemens Healthineers AG, Bruker Corp, and DiaSorin SpA, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com